Iron chelator alleviates tubulointerstitial fibrosis in diabetic nephropathy rats by inhibiting the expression of tenascinC and other correlation factors

Endocrine

Volumn 44, Issue 3, 2013, Pages 666-674

  Zou, Chunbo ^a   Xie, Rujuan ^a   Bao, Yushi ^a   Liu, Xiaogang ^a   Sui, Manshu ^a   Suhong, M ^a   Li, Shuang ^a   Yin, Huiqing ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Diabetic nephropathy; Iron chelator; TenascinC; Tubulointerstitial fibrosis

Indexed keywords

COLLAGEN TYPE 4; DEFERIPRONE; FERRITIN; GLUCOSE; IRON; MALONALDEHYDE; MESSENGER RNA; SUPEROXIDE DISMUTASE; TENASCIN; TRANSFERRIN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLLAGEN IV GENE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; FERRITIN BLOOD LEVEL; FIBRONECTIN 1 GENE; GENE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; IRON BLOOD LEVEL; KIDNEY FIBROSIS; MALE; MICROALBUMINURIA; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; RENAL PROTECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TENASCIN C GENE; TRANSFORMING GROWTH FACTOR BETA1 GENE; TUBULOINTERSTITIAL FIBROSIS; WESTERN BLOTTING;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; IRON CHELATING AGENTS; KIDNEY; MALE; MALONDIALDEHYDE; PYRIDONES; RATS; RATS, WISTAR; SUPEROXIDE DISMUTASE; TENASCIN;

EID: 84890787825     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-013-9907-0     Document Type: Article

References (40)

1. R.E. Gilbert, M.E. Cooper, The tubulointerstitium in progressive diabetic kidney disease: More than an aftermath of glomerular injury? Kidney Int. 56, 1627-1637 (1999)
2. T.A. Wynn, Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J. Clin. Invest. 117, 524-529 (2007)
3. Min Heun Cho, M.D. Korean, J Pediatr Renal fibrosis. Korean J. Pediatr. 53, 735-740 (2010)
4. F.N. Ziyadeh, Mediators of diabetic renal disease: the case for TGF-β as the major mediator. J. Am. Soc. Nephrol. 15, S55-S57 (2004)
5. G. Remuzzi, A. Benigni, A. Remuzzi, Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J. Clin. Invest. 116, 288-296 (2006)
6. W.S. To, K.S. Midwood, Cryptic domains of tenascin-C differentially control fibronectin fibrillogenesis. Matrix Biol. 29, 573-585 (2010)
7. G.S. Schultz, A. Wysocki, Interactions between extracellular matrix and growth factors in wound healing. Wound Repair Regen. 17, 153-162 (2009)
8. M. Hadziahmetovic, Y. Song, N. Wolkow, The oral iron chelator deferiprone protects against iron overload-induced retinal degeneration. Invest. Ophthalmol. Vis. Sci. 52(2), 959-968 (2011)
9. G.J. Kontoghiorghes, A. Kolnagou, C.T. Peng, Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases. Expert Opin. Drug. Saf. 9, 201-206 (2010)
10. B.J. Nankivell, R.A. Boadle, D.C.H. Harris, Iron accumulation in human chronic renal disease. Am. J. Kidney Dis. 20, 504-580 (1992)
11. Y. Naito, A. Fujii, H. Sawada, Effect of iron restriction on renal damage and mineralocorticoid receptor signaling in a rat model of chronic kidney disease. J. Hypertens. 30(11), 2192-2201 (2012)
12. B.J. Nankivell, J. Chen, R.A. Boadle, The role of tubular iron accumulation in the remnant kidney. J. Am. Soc. Nephrol. 4, 1598-1607 (1994)
13. N.G. Forouhi, A.H. Harding, Allison M, Elevated serum ferritin levels predict new-onset type 2 diabetes: results from the EPIC-Norfolk prospective study. Diabetologia 50, 949-956 (2007)
14. Emanuele Angelucci, Pietro Muretto, Antonio Nicolucci, Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 100, 17-21 (2002)
15. Vasilios Berdoukas, Kallistheni Farmaki, Susan Carson, Treating thalassemia major-related iron overload: the role of deferiprone. J Blood Med. 3, 119-129 (2012)
16. S. Rodrat, P. Yamanont, J. Tankanitlert, Comparison of pharmacokinetics and urinary iron excretion of two single doses of deferiprone in β-thalassemia/hemoglobin E patients. Pharmacology 90(1-2), 88-94 (2012)
17. Sudhihr V. Shah, Mohan M. Rajapurkar, The role of labile iron in kidney disease and treatment with chelation. Hemoglobin 33, 378-385 (2009)
18. Ying Li, Qiong Chen, Fu-You Liu, Norcantharidin attenuates tubulointerstitial fibrosis in rat models with diabetic nephropathy. Ren. Fail. 33, 233-241 (2011)
19. M. Sugano, H. Yamato, T. Hayashi, High-fat diet inlow-dose- streptozotocin-treated heminephrectomized rats induces all features of human type 2 diabetic nephropathy: a new rat model of diabetic nephropathy. Nutr. Metab. Cardiovasc. Dis. 16(7), 477-484 (2006)
20. Chi Young Shim, Sungha Park, Jung-Sun Kim, Association of plasma retinol-binding protein 4, adiponectin, and high molecular weight adiponectin with insulin resistance in non-diabetic hypertensive patients. Yonsei Med. J. 51, 375-384 (2010)
21. T.A. O'Sullivan, A.P. Bremner, S. O'Neill, Glycemic load is associated with insulin resistance in older Australian women. Eur. J. Clin. Nutr. 64, 80-87 (2010)
22. J.W.Tang Meng, Y. Wang, Astragaloside IV synergizes with ferulic acid to inhibit renal tubulointerstitial fibrosis in rats with obstructive nephropathy LQ. Br. J. Pharmacol. 162, 1805-1818 (2011)
23. V. Thallas-Bonke, S.R. Thorpe, T. Melinda, Inhibition of NADPH Oxidase Prevents Advanced Glycation End Product-Mediated Damage in Diabetic Nephropathy Through a Protein Kinase C-α-Dependent Pathway. Diabetes 57, 460-469 (2008)
24. G. Abbruzzese, G. Cossu, M. Balocco, A pilot trial of deferiprone for neurodegeneration with brain iron accumulation. Haematologica 96, 1708-1711 (2011)
25. D.S. Kalinowski, D.R. Richardson, The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer. Pharmacol. Rev. 57, 547-583 (2005)
26. B.J. Nankivell, J. Chen, R.A. Boadle, D.C.H. Harris, The role of tubular iron accumulation in the remnant kidney. J. Am. Soc. Nephrol. 4, 1598-1607 (1994)
27. D.C. Harris, C. Tay, B.J. Nankivell, Lysosomal iron accumulation and tubular damage in rat puromycin nephrosis and ageing. Clin. Exp. Pharmacol. Physiol. 21, 73-81 (1994)
28. S. Fujimoto, N. Kawakami, A. Ohara, Nonenzymatic glycation of transferrin: decrease of Iron-binding capacity and increase of oxygen radical production. Biol. Pharm. Bull. 18, 396-400 (1995)
29. D.H. Lee, A.R. Folsom, D.R.J. Jacobs, Dietary iron intake and type 2 diabetes incidence in postmenopausal women: the Iowa Women's Health Study. Diabetologia 47, 185-194 (2004)
30. A. Inada, K. Nagai, H. Arai, Establishment of a diabetic mouse model with progressive diabetic nephropathy. Am. J. Pathol. 167, 327-336 (2005)
31. Y. Sun, J. Zhang, J.Q. Zhang, Local angiotensin II and transforming growth factor-beta1 in renal fibrosis of rats. Hypertension 35(5), 1078-1084 (2000)
32. G.A. McDonald, P. Sarkar, H. Rennke, Relaxin increases ubiquitin-dependent degradation of fibronectin in vitro and ameliorates renal fibrosis in vivo. Am. J. Physiol. Renal. Physiol. 285(1), F59-F67 (2003)
33. K. Uchio, N. Manabe, M. Yamaguchi-Yamada, Changes in the localization of type I, III and IV collagen mRNAs in the kidneys of hereditary nephritic (ICGN) mice with renal fibrosis. J. Vet. Med. Sci. 66(2), 123-128 (2004)
34. T. Pantsulaia, Role of TGF-beta in pathogenesis of diabetic nephropathy. Georgian Med. News. 131, 13-18 (2006)
35. Y. Nishitani, M. Iwano, Y. Yamaguchi, Fibroblast-specific protein 1 is a specific prognostic marker for renal survival in patients with IgAN. Kidney Int. 68, 1078-1085 (2005)
36. N. Khalil, Y.D. Xu, R. O'Connor, Proliferation of pulmonary interstitial fibroblasts is mediated by transforming growth factor-beta1-induced release of extracellular fibroblast growth factor-2 and phosphorylation of p38 MAPK and JNK. J. Biol. Chem. 280, 43000-43009 (2005)
37. M. Jinnin, H. Ihn, Y. Asano, Tenascin-C upregulation by transforming growth factor-beta in human dermal fibroblasts involves. Oncogene 23, 1656-1667 (2004)
38. Y. Gorin, K. Block, J. Hernandez, Nox4 NAD(P)H Oxidase Mediates Hypertrophy and Fibronectin Expression in the Diabetic Kidney. J. Biol. Chem. 280(47), 39616-39626 (2005)
39. A. El-Karef, T. Yoshida, E.C. Gabazza, Deficiency of tenascin-C attenuates liver fibrosis in immune-mediated chronic hepatitis in mice. J. Pathol. 211(1), 86-94 (2007)
40. W.A. Carey, G.D. Taylor, W.B. Dean, Tenascin-C deficiency attenuates TGF-ß-mediated fibrosis following murine lung injury. Am. J. Physiol. Lung Cell. Mol. Physiol. 299(6), L785-L793 (2010)